Survey of Ophthalmology
Volume 47, Issue 3 , Pages 215-238 , May 2002

Primary Anti-Phospholipid Antibody Syndrome (APS) Current Concepts

  • Omar M Durrani, FRCS

      Affiliations

    • Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
    • Corresponding Author InformationReprint address: Omar M Durrani, Birmingham & Midland Eye Centre, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QU, United Kingdom
    • ,
  • Caroline Gordon, MD, FRCP

      Affiliations

    • Department of Rheumatology, Division of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
    • ,
  • Philip I Murray, FRCOphth, PhD

      Affiliations

    • Academic Unit of Ophthalmology, Division of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom

References 

  1. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin (Pulmonary Embolism Prevention (PEP) trial). Lancet. 2000;355:1295–1302
  2. Thrombosis prevention trial (randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Councils General Practice Research F). Lancet. 1998;351:233–241
  3. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS). Neurology. 1997;48:91–94
  4. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol. 1997;42:857–865
  5. Abu El-Asrar AM, Abdel Gader AG, Al-Amro S, Al-Momen AK. Hypercoagulable states in patients with retinal venous occlusion. Doc Ophthalmol. 1998;95:133–143
  6. Acheson JF, Gregson RM, Merry P, Schulenburg WE. Vaso-occlusive retinopathy in the primary anti-phospholipid antibody syndrome. Eye. 1991;5:48–55
  7. Alarcon-Segovia D, Perez-Ruiz A, Villa AR. Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2000;15:157–161
  8. Amengual O, Atsumi T, Khamashta MA, et al.  Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol. 1996;35:1239–1243
  9. Amital H, Langevitz P, Levy Y, et al.  Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome (a clue to the origin of the disease). Clin Exp Rheumatol. 1999;17:99–102
  10. Andrews PA, Frampton G, Cameron JS. Antiphospholipid syndrome and systemic lupus erythematosus. Lancet. 1993;342:988–989
  11. Ang LP, Yap EY, Fam HB. Bilateral choroidal infarction in a patient with antiphospholipid syndrome (a case report). Clin Experiment Ophthalmol. 2000;28:326–328
  12. Armas JB, Dantas J, Mendonca D, et al.  Anticardiolipin and antinuclear antibodies in cancer patients—a case control study. Clin Exp Rheumatol. 2000;18:227–232
  13. Asherson RA. The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus. 1998;7(Suppl):S55–S62
  14. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508–512
  15. Asherson RA. Antiphospholipid antibodies, malignancies and paraproteinemias. J Autoimmun. 2000;15:117–122
  16. Asherson RA, Baguley E, Pal C, Hughes GR. Antiphospholipid syndrome (five year follow up). Ann Rheum Dis. 1991;50:805–810
  17. Asherson RA, Cervera R. The antiphospholipid syndrome (a syndrome in evolution). Ann Rheum Dis. 1992;51:147–150
  18. Asherson RA, Khamashta MA, Ordi-Ros J. The primary antiphospholipid syndrome (major clinical and serological features). Medicine (Baltimore). 1989;68:366–374
  19. Asherson RA, Merry P, Acheson JF, et al.  Antiphospholipid antibodies (a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the primary antiphospholipid syndrome). Ann Rheum Dis. 1989;48:358–361
  20. Asherson RA, Piette JC. The catastrophic antiphospholipid syndrome 1996 (acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients). Lupus. 1996;5:414–417
  21. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome—molecular mimicry?. J Rheumatol. 2000;27:12–14
  22. Atsumi T, Khamashta MA, Amengual O, et al.  Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI) (a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system). Clin Exp Immunol. 1998;112:325–333
  23. Bajaj MS, Ameria A, Bajaj SP. Tissue factor pathway inhibitor-A regulator of tissue factor induced coagulation. In:  Green D editors. Anticoagulants (Physiologic, Pathologic and Pharmacologic). Boca Raton, Florida: CRC Press; 1994;p. 41–65
  24. Bauer K, Rosenberg RD: Control of coagulation reactions, in Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds): Williams Hematology. New York, McGraw-Hill, 1995, ed 5, pp 1239–91
  25. Bevers EM, Comfurius P, Dekkers DW, Harmsma M. Regulatory mechanism of transmembrane phospholipid distributions and pathophysiological implications of transbilayer lipid scrambling. Lupus. 1998;7(Suppl 2):S126–S131
  26. Bick RL. The antiphospholipid-thrombosis syndromes. Fact, fiction, confusion, and controversy. Am J Clin Pathol. 1993;100:477–480
  27. Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes. Haemostasis. 1999;29:100–110
  28. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost. 1999;25:333–350
  29. Bolling JP, Brown GC. The antiphospholipid antibody syndrome. Curr Opin Ophthalmol. 2000;11:211–213
  30. Branch DW, Peaceman AM, Druzin M, et al.  A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000;182:122–127
  31. Branch DW, Silver RM. Criteria for antiphospholipid syndrome (early pregnancy loss, fetal loss, or recurrent pregnancy loss?). Lupus. 1996;5:409–413
  32. Branch DW, Silver RM, Blackwell JL, et al.  Outcome of treated pregnancies in women with antiphospholipid syndrome (an update of the Utah experience). Obstet Gynecol. 1992;80:614–620
  33. Brey RL. Differential diagnosis of central nervous system manifestations of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15:133–138
  34. Brey RL, Escalante A. Neurological manifestations of antiphospholipid antibody syndrome. Lupus. 1998;7(Suppl 2):S67–S74
  35. Brey RL, Gharavi AE, Lockshin MD. Neurologic complications of antiphospholipid antibodies. Rheum Dis Clin North Am. 1993;19:833–850
  36. Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology. 1990;40:1190–1196
  37. Cailleux N, Marie I, Jeanton M, et al.  [Are antiphospholipid antibodies thrombogenic in the course of human immunodeficiency virus infection?. ]. J Mal Vasc. 1999;24:53–56
  38. Camerlingo M, Casto L, Censori B, et al.  Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand. 1995;92:69–71
  39. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost. 1995;73:529–534
  40. Cantalapiedra A, Avello AG, Navarro JL, Cesar JM. Familial occurrence of primary antiphospholipid syndrome. Thromb Res. 1999;95:127–129
  41. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke. 1997;28:2363–2369
  42. Carreras LO, Forastiero RR. Pathogenic role of antiprotein-phospholipid antibodies. Haemostasis. 1996;26(Suppl 4):S340–S357
  43. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome?. J Autoimmun. 2000;15:163–172
  44. Carreras LO, Martinuzzo ME, Maclouf J. Antiphospholipid antibodies, eicosanoids and expression of endothelial cyclooxygenase-2. Lupus. 1996;5:494–497
  45. Castanon C, Amigo MC, Banales JL, et al.  Ocular vaso-occlusive disease in primary antiphospholipid syndrome. Ophthalmology. 1995;102:256–262
  46. Castellino G, Cuadrado MJ, Godfrey T, et al.  Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment. Ann Rheum Dis. 2001;60:527–530
  47. Cervera R. Recent advances in antiphospholipid antibody-related valvulopathies. J Autoimmun. 2000;15:123–125
  48. Clark AL, Branch DW, Silver RM, et al.  Pregnancy complicated by the antiphospholipid syndrome (outcomes with intravenous immunoglobulin therapy). Obstet Gynecol. 1999;93:437–441
  49. Cobo Soriano R, Aparicio Hernandez-Lastras MJ, Seoane E, et al: [Retinal thrombosis in young patients. Immunological and clinical aspects]. Arch Soc Esp Oftalmol 76:181–8, 2001
  50. Cobo-Soriano R, Sanchez-Ramon S, Aparicio MJ, et al.  Antiphospholipid antibodies and retinal thrombosis in patients without risk factors (a prospective case-control study). Am J Ophthalmol. 1999;128:725–732
  51. Coniglio M, Platania A, Di Nucci GD, et al.  Antiphospholipid-protein antibodies are not an uncommon feature in retinal venous occlusions. Thromb Res. 1996;83:183–188
  52. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258–264
  53. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T. Can neurological manifestations of Hughes (anti-phospholipid) syndrome be distinguished from multiple sclerosis?. Medicine (Baltimore). 2000;79:57–68
  54. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, et al.  Thrombosis in primary antiphospholipid syndrome (a pivotal role for monocyte tissue factor expression). Arthritis Rheum. 1997;40:834–841
  55. Cuadrado MJ, Tinahones F, Camps MT, et al.  Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. QJM. 1998;91:619–626
  56. Cucurull E, Gharavi AE, Diri E, et al.  IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci. 1999;318:55–60
  57. D'Angelo A, Safa O, Crippa L, et al.  Relationship of lupus anticoagulant, anticardiolipin, anti-beta2-GPI and anti-prothrombin autoantibodies with history of thrombosis in patients with the clinical suspicion of APA-syndrome. Thromb Haemost. 1997;78:967–968
  58. de Groot PG, Horbach DA, Derksen RH. Protein C and other cofactors involved in the binding of antiphospholipid antibodies (relation to the pathogenesis of thrombosis). Lupus. 1996;5:488–493
  59. de Larranaga GF, Forastiero RR, Carreras LO, Alonso BS. Different types of antiphospholipid antibodies in AIDS (a comparison with syphilis and the antiphospholipid syndrome). Thromb Res. 1999;96:19–25
  60. De Schryver EL, Gorter JW, Algra A, van Gijn J: [Prevention of vascular complications after cerebral ischemia of arterial origin. European Stroke and Australian Stroke Prevention in Reversible Ischemia Trial (ESPRIT): moderated coagulation, aspirin- dipyridamole combination or aspirin alone?]. Rev Med Interne 20:397–9, 1999
  61. Del Papa N, Raschi E, Catelli L, et al.  Endothelial cells as a target for antiphospholipid antibodies (role of anti-beta 2 glycoprotein I antibodies). Am J Reprod Immunol. 1997;38:212–217
  62. Demirci FY, Kucukkaya R, Ararcay K, Kir N. Ocular involvement in primary antiphospholipid syndrome. Int Ophthalmol. 2000;22:323–329
  63. Derksen RH, de Groot PG. Do we know which patients with the antiphospholipid syndrome should receive long-term high dose anti-coagulation?. J Autoimmun. 2000;15:255–259
  64. Devine DV, Brigden ML. The antiphospholipid syndrome (when does the presence of antiphospholipid antibodies require therapy?). Postgrad Med. 1132;99(5):105–108
  65. Dogulu CF, Kansu T, Kadayifcilar S. The role of IgM isotype anticardiolipin antibodies in occlusive ocular vascular disease (report of two cases with primary antiphospholipid antibody syndrome). Eye. 2000;14(Pt 5):789–790
  66. Dori D, Gelfand YA, Brenner B, Miller B. Cilioretinal artery occlusion (an ocular complication of primary antiphospholipid syndrome). Retina. 1997;17:555–557
  67. Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol. 1989;16:614–617
  68. Drouvalakis KA, Buchanan RR. Phospholipid specificity of autoimmune and drug induced lupus anticoagulants; association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease. J Rheumatol. 1998;25:290–295
  69. Dunn JP, Noorily SW, Petri M, et al.  Antiphospholipid antibodies and retinal vascular disease. Lupus. 1996;5:313–322
  70. Durrani OM, Cameron-Swaby DA, Bowman S, Ainsworth JR. Scleritis as the presenting sign of primary antiphospholipid syndrome. Eye. 2001;15:558–559
  71. Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary antiphospholipid syndrome (functional outcome after 10 years). J Rheumatol. 2000;27:2817–2821
  72. Erlendsson K, Steinsson K, Johannsson JH, Geirsson RT. Relation of antiphospholipid antibody and placental bed inflammatory vascular changes to the outcome of pregnancy in successive pregnancies of 2 women with systemic lupus erythematosus. J Rheumatol. 1993;20:1779–1785
  73. Espinoza LR. Antiphospholipid antibody syndrome (treatment). Lupus. 1996;5:456–457
  74. Fiallo P, Tomasina C, Clapasson A, Cardo PP. Antibodies to beta(2)-glycoprotein I in ischemic stroke. Cerebrovasc Dis. 2000;10:293–297
  75. Finazzi G. The Italian registry of antiphospholipid antibodies. Haematologica. 1997;82:101–105
  76. Ford SE, Kennedy L, Ford PM. Clinicopathologic correlations of antiphospholipid antibodies. An autopsy study. Arch Pathol Lab Med. 1994;118:491–495
  77. Francis JL. Laboratory investigation of hypercoagulability. Semin Thromb Hemost. 1998;24:111–126
  78. Galli M, Barburi T. Prothrombin as a cofactor for antiphospholipid antibodies. Lupus. 1998;7(Suppl):S37–S40
  79. Galli M, Beretta G, Daldossi M, et al.  Different anticoagulant and immunological properties of anti- prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997;77:486–491
  80. Gelfand YA, Dori D, Miller B, Brenner B. Visual disturbances and pathologic ocular findings in primary antiphospholipid syndrome. Ophthalmology. 1999;106:1537–1540
  81. Genvresse I, Buttgereit F, Spath-Schwalbe E, et al.  Arterial thrombosis associated with anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkins lymphoma (a report of two cases). Eur J Haematol. 2000;65:344–347
  82. George J, Shoenfeld Y. The anti-phospholipid (Hughes) syndrome (a crossroads of autoimmunity and atherosclerosis). Lupus. 1997;6:559–560
  83. George JN. Platelets. Lancet. 2000;355:1531–1539
  84. Gharavi AE, Pierangeli SS. Origins of anti-phospholipid antibodies (induction of aPL by viral peptides). Lupus. 1998;7(Suppl 2):S52–S54
  85. Gharavi AE, Pierangeli SS, Harris EN. New developments in viral peptides and APL induction. J Autoimmun. 2000;15:227–230
  86. Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol. 1997;36:970–982
  87. Ginsberg JS, Wells PS, Brill-Edwards P, et al.  Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685–3691
  88. Ginsburg KS, Liang MH, Newcomer L, et al.  Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997–1002
  89. Giordano N, Senesi M, Battisti E, et al.  Antiphospholipid antibodies in patients with retinal vascular occlusions. Acta Ophthalmol Scand. 1998;76:128–129
  90. Giorgi D, Balacco Gabrieli C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS) (clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis). Clin Rheumatol. 1999;18:124–131
  91. Giorgi D, David V, Afeltra A, et al.  Transient visual symptoms in systemic lupus erythematosus and antiphospholipid syndrome. Ocul Immun Inflammation. 2001;9:49–57
  92. Glacet-Bernard A, Bayani N, Chretien P, et al.  Antiphospholipid antibodies in retinal vascular occlusions. A prospective study of 75 patients. Arch Ophthalmol. 1994;112:790–795
  93. Goel N, Ortel TL, Bali D, et al.  Familial antiphospholipid antibody syndrome (criteria for disease and evidence for autosomal dominant inheritance). Arthritis Rheum. 1999;42:318–327
  94. Goldberger E, Elder RC, Schwartz RA, Phillips PE. Vasculitis in the antiphospholipid syndrome. A cause of ischemia responding to corticosteroids. Arthritis Rheum. 1992;35:569–572
  95. Goldstein R, Smith CD, Sengar DPS. MHC class II studies of primary antiphospholipid antibody (APLA) syndrome and of serum antiphospholipid antibodies in systemic lupus erythematosus (SLE). Arthritis Rheum. 1990;33(Suppl):S125
  96. Gonzalez C, Leston A, Garcia-Berrocal B. Antiphosphatidylserine antibodies in patients with autoimmune diseases and HIV-infected patients (effects of Tween 20 and relationship with antibodies to beta2-glycoprotein I). J Clin Lab Anal. 1999;13:59–64
  97. Gordon C, Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Lupus. 1998;7:429–433
  98. Gotoh M, Matsuda J. Induction of anticardiolipin antibody and/or lupus anticoagulant in rabbits by immunization with lipoteichoic acid, lipopolysaccharide and lipid A. Lupus. 1996;5:593–597
  99. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol. 2000;109:704–715
  100. Greco TP, Amos MD, Conti-Kelly AM, et al.  Testing for the antiphospholipid syndrome (importance of IgA anti-beta 2-glycoprotein I). Lupus. 2000;9:33–41
  101. Greiner K, Hafner G, Dick B, et al.  Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol. 1999;128:69–74
  102. Grunewald T, Burmester GR, Schuler-Maue W, et al.  Anti-phospholipid antibodies and CD5+ B cells in HIV infection. Clin Exp Immunol. 1999;115:464–471
  103. Guglielmone H, Vitozzi S, Elbarcha O, Fernandez E. Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Ann Rheum Dis. 2001;60:500–504
  104. Hahn BH. Systemic lupus erythematosus. In:  Fauci AS editors. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 1998;
  105. Hamsten A, Norberg R, Bjorkholm M, et al.  Antibodies to cardiolipin in young survivors of myocardial infarction (an association with recurrent cardiovascular events). Lancet. 1986;1:113–116
  106. Hanly JG, Hong C, Issekutz A. Beta 2-glycoprotein I and anticardiolipin antibody binding to resting and activated cultured human endothelial cells. J Rheumatol. 1996;23:1543–1549
  107. Harris EN, Baguley E, Asherson RA, Hughes GRV. Clinical and serological features of the antiphospholipid syndrome (APS). Br J Rheumatol. 1987;26(Suppl):19
  108. Harris EN, Pierangeli SS. Functional effects of anticardiolipin antibodies. Lupus. 1996;5:372–377
  109. Harris EN, Pierangeli SS, Gharavi AE. Diagnosis of the antiphospholipid syndrome (a proposal for use of laboratory tests). Lupus. 1998;7(Suppl 2):S144–S148
  110. Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women?. Am J Obstet Gynecol. 1991;165:1272–1277
  111. Hartung K, Coldewey R, Corvetta A, et al.  MHC gene products and anticardiolipin antibodies in systemic lupus erythematosus results of a multicenter study. SLE Study Group. Autoimmunity. 1992;13:95–99
  112. Hartung K, Coldewey R, Corvetta A, et al.  MHC gene products and anticardiolipin antibodies in systemic lupus erythematosus results of a multicenter study. SLE Study Group. Autoimmunity. 1992;13:95–99
  113. Holschermann H, Hilgendorf A, Kemks-Matthes B. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 2000;69:1837–1848
  114. Hughes GR. The antiphospholipid syndrome and multiple sclerosis. Lupus. 1999;8:89
  115. Hughes GR. The antiphospholipid syndrome (ten years on). Lancet. 1993;342:341–344
  116. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed). 1983;287:1088–1089
  117. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 1986;13:486–489
  118. Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol. 1995;26:716–724
  119. Jennings I, Kitchen S, Woods TA, et al.  Potentially clinically important inaccuracies in testing for the lupus anticoagulant (an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation). Thromb Haemost. 1997;77:934–937
  120. Jesty J, Nemerson Y. The Pathways of blood coagulation. New York: Mc Graw-Hill; 1995;ed 5
  121. Joseph J, Scopelitis E. Seronegative antiphospholipid syndrome associated with plasminogen activator inhibitor. Lupus. 1994;3:201–203
  122. Joseph JE, Harrison P, Mackie IJ, Machin SJ. Platelet activation markers and the primary antiphospholipid syndrome (PAPS). Lupus. 1998;7(Suppl 2):S48–S51
  123. Kaaja R, Julkunen H, Ammala P, et al.  Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand. 1993;72:63–66
  124. Kalogeropoulos CD, Spyrou P, Stefaniotou MI, et al.  Anticardiolipin antibodies and occlusive vascular disease of the eye (prospective study). Doc Ophthalmol. 1998;95:109–120
  125. Kamboh MI, Mehdi H. Genetics of apolipoprotein H (beta2-glycoprotein I) and anionic phospholipid binding. Lupus. 1998;7(Suppl 2):S10–S13
  126. Kandiah DA, Sheng YH, Krilis SA. beta 2-Glycoprotein I (target antigen for autoantibodies in the antiphospholipid syndrome). Lupus. 1996;5:381–385
  127. Kent D, Hickey-Dwyer M, Clark D. Long-term follow-up of ischaemic retinopathy in the antiphospholipid syndrome with lupus-like disease. Eye. 2000;14:313–317
  128. Khamashta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmun. 2000;15:249–253
  129. Khamashta MA. Management of anti-phospholipid syndrome. CPD Rheumatology. 1999;1:22–29
  130. Khamashta MA. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus. 1998;7(Suppl 2):S162–S165
  131. Khamashta MA, Cuadrado MJ, Mujic F, et al.  The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993–997
  132. Kingsmore SF, Goel N, Gourley IS. Clinial and genetic features of 12 families with an inherited primary antiphospholipid antibody syndrome. Arthritis Rheum. 1994;37(Suppl):S296
  133. Kleiner RC, Najarian LV, Schatten S, et al.  Vaso-occlusive retinopathy associated with antiphospholipid antibodies (lupus anticoagulant retinopathy). Ophthalmology. 1989;96:896–904
  134. Koike T, Ichikawa K, Kasahara H, Atsumi T. Epitopes on beta2-GPI recognized by anticardiolipin antibodies. Lupus. 1998;7(Suppl 2):S14–S17
  135. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol. 1994;153:1328–1332
  136. Krnic-Barrie S, OConnor CR, Looney SW, et al.  A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med. 1997;157:2101–2108
  137. Kutteh WH. Antiphospholipid antibodies and reproduction. J Reprod Immunol. 1997;35:151–171
  138. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss (treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone). Am J Obstet Gynecol. 1996;174:1584–1589
  139. Kutteh WH, Rote NS, Silver R. Antiphospholipid antibodies and reproduction (the antiphospholipid antibody syndrome). Am J Reprod Immunol. 1999;41:133–152
  140. Lakos G, Kiss E, Regeczy N, et al.  Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies (importance of IgA isotype). Clin Exp Immunol. 1999;117:574–579
  141. Lamprecht P, deGroot K, Schnabel A, et al.  Anticardiolipin antibodies and antibodies to beta(2)-glycoprotein I in patients with Wegeners granulomatosis. Rheumatology (Oxford). 2000;39:568–570
  142. Leder AN, Flansbaum B, Zandman-Goddard G, et al.  Antiphospholipid syndrome induced by HIV. Lupus. 2001;10:370–374
  143. Lellouche F, Martinuzzo M, Said P, et al.  Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood. 1991;78:2894–2899
  144. Leo-Kottler B, Klein R, Berg PA, Zrenner E. Ocular symptoms in association with antiphospholipid antibodies. Graefes Arch Clin Exp Ophthalmol. 1998;236:658–668
  145. Levine JS, Koh JS, Subang R, Rauch J. Apoptotic cells as immunogen and antigen in the antiphospholipid syndrome. Exp Mol Pathol. 1999;66:82–98
  146. Levine SR, Brey RL, Sawaya KL, et al.  Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol. 1995;38:119–124
  147. Levine SR, Salowich-Palm L, Sawaya KL, et al.  IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke. 1997;28:1660–1665
  148. Levy RA. Clinical manifestations of the aPL syndrome. Lupus. 1996;5:393–397
  149. Levy RA, Avvad E, Oliveira K, Porto LC. Placental pathology in antiphospholipid syndrome. Lupus. 1998;7(Suppl 2):S81–S85
  150. Lima F, Khamashta MA, Buchanan NM, et al.  A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14:131–136
  151. Liu E, Nijhawan N, Gladman D, et al.  Primary antiphospholipid syndrome and neovascular glaucoma. Can J Ophthalmol. 1999;34:349–352
  152. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 2000;43:440–443
  153. Love PE, Santoro SA. Antiphospholipid antibodies (anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance). Ann Intern Med. 1990;112:682–698
  154. Maaravi Y, Raz E, Gilon D, Rubinow A. Cerebrovascular accident and myocardial infarction associated with anticardiolipin antibodies in a young woman with systemic lupus erythematosus. Ann Rheum Dis. 1989;48:853–855
  155. MacLean MA, Cumming GP, McCall F, et al.  The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol. 1994;101:103–106
  156. Manna R, Latteri M, Cristiano G, et al.  Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica (a study of 40 cases). Br J Rheumatol. 1998;37:208–210
  157. Mant MJ, Stang L, Etches WS. Warfarin monitoring in patients with anticardiolipin antibodies, but without lupus anticoagulants. Thromb Res. 2000;99:477–482
  158. Martinuzzo ME, Forastiero RR, Carreras LO. Anti beta 2 glycoprotein I antibodies (detection and association with thrombosis). Br J Haematol. 1995;89:397–402
  159. Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost. 1993;70:667–671
  160. Maruyama I. Biology of endothelium. Lupus. 1998;7(Suppl 2):S41–S43
  161. Matsuura E, Kobayashi K, Yasuda T, Koike T. Antiphospholipid antibodies and atherosclerosis. Lupus. 1998;7(Suppl 2):S135–S139
  162. Meroni PL, Del Papa N, Raschi E. Beta2-Glycoprotein I as a cofactor for anti-phospholipid reactivity with endothelial cells. Lupus. 1998;7(Suppl 2):S44–S47
  163. Meroni PL, Raschi E, Camera M, et al.  Endothelial activation by aPL (a potential pathogenetic mechanism for the clinical manifestations of the syndrome). J Autoimmun. 2000;15:237–240
  164. Miret C, Cervera R, Reverter JC, et al.  Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event (transient seronegative antiphospholipid syndrome?). Clin Exp Rheumatol. 1997;15:541–544
  165. Miserocchi E, Baltatzis S, Foster CS. Ocular features associated with anticardiolipin antibodies (a descriptive study). Am J Ophthalmol. 2001;131:451–456
  166. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med. 1997;127:177–185
  167. Montalban J, Codina A, Ordi J, et al.  Antiphospholipid antibodies in cerebral ischemia. Stroke. 1991;22:750–753
  168. Munoz-Rodriguez FJ, Font J, Cervera R, et al.  Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum. 1999;29:182–190
  169. Najmey SS, Keil LB, Adib DY, DeBari VA. The association of antibodies to beta 2 glycoprotein I with the antiphospholipid syndrome (a meta-analysis). Ann Clin Lab Sci. 1997;27:41–46
  170. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome (prevalence, clinical features, and treatment). Semin Arthritis Rheum. 1997;27:27–35
  171. Oosting JD, Derksen RH, Bobbink IW, et al.  Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S (an explanation for their pathogenic mechanism?). Blood. 1993;81:2618–2625
  172. Out HJ, Bruinse HW, Christiaens GC, et al.  Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann Rheum Dis. 1991;50:553–557
  173. Ozguroglu M, Arun B, Erzin Y, et al.  Serum cardiolipin antibodies in cancer patients with thromboembolic events. Clin Appl Thromb Hemost. 1999;5:181–184
  174. Palimar P, Cota N. Asymptomatic vaso-occlusive retinopathy in Hughes syndrome. Eye. 1998;12:320–321
  175. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al.  Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989;86:1372–1376
  176. Parazzini F, Acaia B, Faden D, et al.  Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol. 1991;77:854–858
  177. Peaceman AM, Rehnberg KA. The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant. Am J Obstet Gynecol. 1995;173:1391–1396
  178. Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost. 1999;81:256–258
  179. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15:145–151
  180. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am. 1997;81:151–177
  181. Petri M, Golbus M, Anderson R, et al.  Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. Arthritis Rheum. 1987;30:601–606
  182. Petrovas C, Vlachoyiannopoulos PG, Kordossis T, Moutsopoulos HM. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome (comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI). J Autoimmun. 1999;13:347–355
  183. Pierangeli SS, Gharavi AE, Harris EN. Anticardiolipin testing. In:  Khamashta MA editors. Hughes Syndrome (Antiphospholipid Syndrome). Springer-Verlag: London; 2000;p. 205–213
  184. Pierangeli SS, Harris EN. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus. 1996;5:451–455
  185. Pierangeli SS, Stewart M, Silva LK, Harris EN: An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol 25:156–60, 1998
  186. Piette JC, Wechsler B, Frances C, et al.  Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol. 1993;20:1802–1804
  187. Pradier O, Surquin M, Stordeur P, et al.  Monocyte procoagulant activity induced by in vivo administration of the OKT3 monoclonal antibody. Blood. 1996;87:3768–3774
  188. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314:253–257
  189. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995;10:3301–3304
  190. Rand JH. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield (a thrombogenic mechanism for the antiphospholipid syndrome). J Autoimmun. 2000;15:107–111
  191. Rand JH. Antiphospholipid antibody syndrome (new insights on thrombogenic mechanisms). Am J Med Sci. 1998;316:142–151
  192. Rao LV, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood. 1996;88:4173–4182
  193. Reber G, Arvieux J, Comby E, et al.  Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe dEtudes sur lHemostase et la Thrombose). Thromb Haemost. 1995;73:444–452
  194. Reino S, Munoz-Rodriguez FJ, Cervera R, et al.  Optic neuropathy in the primary antiphospholipid syndrome (report of a case and review of the literature). Clin Rheumatol. 1997;16:629–631
  195. Riley RS, Friedline J, Rogers JS. Antiphospholipid antibodies (standardization and testing). Clin Lab Med. 1997;17:395–430
  196. Rojas-Rodriguez J, Garcia-Carrasco M, Ramos-Casals M, et al.  Catastrophic antiphospholipid syndrome (clinical description and triggering factors in 8 patients). J Rheumatol. 2000;27:238–240
  197. Rosove MH, Brewer PM. Antiphospholipid thrombosis (clinical course after the first thrombotic event in 70 patients). Ann Intern Med. 1992;117:303–308
  198. Roubey RA. Mechanisms of autoantibody-mediated thrombosis. Lupus. 1998;7(Suppl 2):S114–S119
  199. Roubey RA. Antigenic specificities of antiphospholipid autoantibodies (implications for clinical laboratory testing and diagnosis of the antiphospholipid syndrome). Lupus. 1996;5:425–430
  200. Sammaritano LR. Significance of aPL IgG subclasses. Lupus. 1996;5:436–439
  201. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med. 1998;104:332–338
  202. Schved JF, Dupuy-Fons C, Biron C, et al.  A prospective epidemiological study on the occurrence of antiphospholipid antibody (the Montpellier Antiphospholipid (MAP) Study). Haemostasis. 1994;24:175–182
  203. Seisdedos L, Munoz-Rodriguez FJ, Cervera R, et al.  Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus. 1997;6:285–286
  204. Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies (a 10 year follow- up of 52 patients). Lupus. 1998;7:3–6
  205. Sheng Y, Hanly JG, Reddel SW, et al.  Detection of antiphospholipid antibodies (a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)- glycoprotein I and prothrombin). Clin Exp Immunol. 2001;124:502–508
  206. Sheng Y, Kandiah DA, Krilis SA. Beta2-Glycoprotein I (target antigen for antiphospholipid antibodies. Immunological and molecular aspects). Lupus. 1998;7(Suppl 2):S5–S9
  207. Shi W, Krilis SA, Chong BH, et al.  Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med. 1990;20:231–236
  208. Shibata S, Harpel PC, Gharavi A, et al.  Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood. 1994;83:2532–2540
  209. Simantov R, Lo SK, Gharavi A, et al.  Antiphospholipid antibodies activate vascular endothelial cells. Lupus. 1996;5:440–441
  210. Simioni P, Prandoni P, Zanon E, et al.  Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost. 1996;76:187–189
  211. Smith JR, Chng H, Chee S. Primary antiphospholipid syndrome masquerading as diabetic retinopathy. Jpn J Ophthalmol. 2001;45:105–108
  212. Snyers B, Lambert M, Hardy JP. Retinal and choroidal vaso-occlusive disease in systemic lupus erythematosus associated with antiphospholipid antibodies. Retina. 1990;10:255–260
  213. Takeya H, Mori T, Gabazza EC, et al.  Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. J Clin Invest. 1997;99:2260–2268
  214. Tektonidou MG, Ioannidis JP, Boki KA, et al.  Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM. 2000;93:523–530
  215. Tektonidou MG, Ioannidis JP, Boki KA, et al.  Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM. 2000;93:523–530
  216. The WARSS, APASS, PICSS, HAS and genesis study groups . The feasibility of a collaborative double-blind study using an anticoagulant. Cerebrovascular Disease. 1997;7:100–112
  217. Tincani A, Spatola L, Cinquini M, Cattaneo R. Anti beta2-glycoprotein I antibodies (clinical significance). Lupus. 1998;7(Suppl 2):107–109
  218. Triplett DA. Antiphospholipid-protein antibodies (clinical use of laboratory test results(identification, predictive value, treatment)). Haemostasis. 1996;26(Suppl 4):S358–S367
  219. Undas A, Brummel KE, Musial J, et al.  Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103:2248–2253
  220. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus. 1998;7(Suppl 2):S132–S134
  221. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus. 1996;5:442–447
  222. Vaarala O, Manttari M, Manninen V, et al.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23–27
  223. Vaarala O, Puurunen M, Manttari M. Antibodies to prothrombin a risk of myocardial infarction in middle-aged men. Thromb Haemost. 1996;75:456–460
  224. Vermylen J, Van Geet C, Amout J. Antibody-mediated thrombosis (relation to the antiphospholipid syndrome). Lupus. 1998;7(Suppl 2):S63–S66
  225. Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke. 1998;29:2245–2253
  226. Vianna JL, Khamashta MA, Ordi-Ros J, et al.  Comparison of the primary and secondary antiphospholipid syndrome (a European Multicenter Study of 114 patients). Am J Med. 1994;96:3–9
  227. Vila P, Hernandez MC, Lopez-Fernandez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 1994;72:209–213
  228. Wahl DG, Guillemin F, de Maistre E, et al.  Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998;7:15–22
  229. Weber M, Hayem G, DeBandt M, et al.  The family history of patients with primary or secondary antiphospholipid syndrome (APS). Lupus. 2000;9:258–263
  230. Welsch S, Branch DW. Antiphospholipid syndrome in pregnancy. Obstetric concerns and treatment. Rheum Dis Clin North Am. 1997;23:71–84
  231. Wiechens B, Schroder JO, Potzsch B, Rochels R. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol. 1997;123:848–850
  232. Wilson WA, Gharavi AE. Genetic risk factors for aPL syndrome. Lupus. 1996;5:398–403
  233. Wilson WA, Gharavi AE, Koike T, et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome (report of an international workshop). Arthritis Rheum. 1999;42:1309–1311
  234. Yang MH, Fan FS, Chen PM, et al.  Venous gangrene in a patient with adenocarcinoma of the lung. Jpn J Clin Oncol. 2000;30:276–278
  235. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555–559
  236. Zanon E, Prandoni P, Vianello F, et al.  Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism (prevalence and association with recurrent thromboembolism). Thromb Res. 1999;96:269–274
  237. Ziporen L, Goldberg I, Arad M, et al.  Libman-Sacks endocarditis in the antiphospholipid syndrome (immunopathologic findings in deformed heart valves). Lupus. 1996;5:196–205
  238. Zuckerman E, Toubi E, Shiran A, et al.  Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients (a controlled prospective study). Am J Med. 1996;101:381–386

PII: S0039-6257(02)00289-8

Survey of Ophthalmology
Volume 47, Issue 3 , Pages 215-238 , May 2002

Article Tools

* Image Usage & Resolution